Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 15;47(4):249-54.
doi: 10.1016/j.bcmd.2011.07.006. Epub 2011 Aug 30.

Uroporphyria in the Cyp1a2-/- mouse

Affiliations

Uroporphyria in the Cyp1a2-/- mouse

John D Phillips et al. Blood Cells Mol Dis. .

Abstract

Cytochrome P4501A2 (Cyp1a2) is important in the development of uroporphyria in mice, a model of porphyria cutanea tarda in humans. Heretofore, mice homozygous for the Cyp1a2-/- mutation do not develop uroporphyria with treatment regimens that result in uroporphyria in wild-type mice. Here we report uroporphyria development in Cyp1a2-/- mice additionally null for both alleles of the hemochromatosis (Hfe) gene and heterozygous for deletion of the uroporphyrinogen decarboxylase (Urod) gene (genotype: Cyp1a2-/-;Hfe-/-;Urod+/-), demonstrating that upon adding porphyria-predisposing genetic manipulations, Cyp1a2 is not essential. Cyp1a2-/-;Hfe-/-;Urod+/- mice were treated with various combinations of an iron-enriched diet, parenteral iron-dextran, drinking water containing δ-aminolevulinic acid and intraperitoneal Aroclor 1254 (a polychlorinated biphenyl mixture) and analyzed for uroporphyrin accumulation. Animals fed an iron-enriched diet alone did not develop uroporphyria but uroporphyria developed with all treatments that included iron supplementation and δ-aminolevulinic acid, even with a regimen without Aroclor 1254. Hepatic porphyrin levels correlated with low UROD activity and high levels of an inhibitor of UROD but marked variability in the magnitude of the porphyric response was present in all treatment groups. Gene expression profiling revealed no major differences between genetically identical triple cross mice exhibiting high and low magnitude porphyric responses from iron-enriched diet and iron-dextran supplementation, and δ-aminolevulinic acid. Even though the variation in porphyric response did not parallel the hepatic iron concentration, the results are compatible with the presence of a Cyp1a2-independent, iron-dependent pathway for the generation of uroporphomethene, the UROD inhibitor required for the expression of uroporphyria in mice and PCT in humans.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Relationship between the presence of an inhibitor of recombinant human uroporphyrinogen decarboxylase and uroporphyringen decarboxylase activity in the cytosol of Cyp1a2−/−;Hfe−/−;Urod+/− mice.
FIGURE 2
FIGURE 2
Summary pathways and reactions responsible for the development of uroporphyria in mice and porphyria cutanea tarda in humans.

Similar articles

Cited by

References

    1. Phillips JD, Kushner JP. The Porphyrias. In: Nathan DG, editor. Nathan and Oski’s Hematology of Infancy and Childhood. Saunders; Philadelphia: 2009. pp. 571–612.
    1. Cam C, Nigogosyan G. Acquired Toxic Porphyria Cutanea Tarda due to Hexachlorobenzene. JAMA. 1963;183:90–93. - PubMed
    1. Nebert DW, Petersen DD, Fornace AJ., Jr Cellular responses to oxidative stress: the [Ah] gene battery as a paradigm. Environ Health Perspect. 1990;88:13–25. - PMC - PubMed
    1. Franklin MR, Phillips JD, Kushner JP. Attenuation of polychlorinated biphenyl induced uroporphyria by iron deprivation. Env Toxicol Pharmacol. 2005;20:417–423. - PubMed
    1. Gorman N, Ross KL, Walton HS, et al. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology. 2002;35:912–21. - PubMed

Publication types

LinkOut - more resources